Pacific Edge shares more than double on US healthcare news

Pacific Edge shares more than double on US healthcare news
Brent Melville
Pacific Edge shares more than doubled in value on confirmation of acceptance under a key US medical regulation for its Cxbladder cancer test. The shares jumped as high as 68 cents from 27 cents yesterday, and were recently at 55 cents, up 104 percent and valuing the company at $379.3 million. The successful standard of care rating from the US Centres for Medicare and Medicaid Services means Pacific Edge will be reimbursed at a rate of US$760 per test from July 1, 2020.  The CMS provides healthcare coverage for all US citizens over the...

More Services

Aussie fund manager Shaws buys Devon Funds
Finance

Aussie fund manager Shaws buys Devon Funds

The deal is the latest tie-up between Australian and NZ funds managers.

Staff reporters 24 Jun 2025
Buy NZ Made's new service trademark sets high bar
Services

Buy NZ Made's new service trademark sets high bar

One certified business says it sets it apart from multinational competitors.

John Anthony 23 Jun 2025
Reel pain: Strikes hit NZ cinemas, profits dive
Services

Reel pain: Strikes hit NZ cinemas, profits dive

Cinema chains in NZ face box office suspense.

Victoria Young 28 May 2025
PEP seeking payday from UP Education
Finance

PEP seeking payday from UP Education

UP Education is a NZ success story in Australia.

Pattrick Smellie 23 Apr 2025